An observational study in Alcoholic Hepatitis and Acute Liver Failure, sponsored by Methodist Health System. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Methodist Health System · Observational
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures. Patient's charts will be accessed on EPIC by the PI or delegated study personnel. The investigator's anticipate completion of this study by January 31, 2022.
106 studies on the registry are indexed under Hepatitis, Alcoholic; 24 are open to participants now.
This study's enrollment of 27 is below the median of 130 across 28 observational studies indexed under Hepatitis, Alcoholic.
Browse Hepatitis, Alcoholic studies →Methodist Health System is the lead sponsor of 169 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients meeting the inclusion criteria (Alcoholic hepatitis, AoCLF; or ALF who underwent at least one round of dialysis using plasma exchange or MARS from January 1, 2019 to December 15, 2020 will be included in the analysis.
Exclusion Criteria:
All patients who underwent MARS at MDMC will be included in the study population.
Transplant free survival mortality
transplant will be measured by date of death, and discharge
Time frame: Rate at 30 days
Difference in Demographics
co-morbidities, etiology of liver failure between those treated with MARS vs. controls
Time frame: Rate at 30 days
Improvement in Transplant
Determine whether treatment with MARS can help facilitate improvement in HE, LOS, and ICU duration.
Time frame: Rate at 30 days
Demographics
age (years), gender (male/female), race (Caucasian, black, Hispanic, Asian, other), BMI (kg/m2)
Time frame: January 1, 2019 to January 31, 2022
Hepatorenal syndrome
Y/N
Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days
Need for vasopressor support
Y/N
Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days
Sepsis (as measured by by QSOFA criteria):
Y/N
Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days
Need for CRRT as documented in the chart:
Y/N
Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days
ICU duration
days of date of ICU duration
Time frame: date of ICU admission and date of discharge (or death)
long term dialysis
Need for long term dialysis (Y/N)
Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Methodist Health System